Applied Therapeutics gets extension of FDA review for rare disease drug

Published on 28 Mar 2024 on Seeking Alpha

The U.S. FDA has delayed the review of Applied Therapeutics' NDA for rare drug disease candidate...

Read the rest of the article

Start tracking your investments with Statfolio

Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder...

Benzinga · via Yahoo Finance 19 Sep 2024

Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, A...

Benzinga · via Yahoo Finance 19 Jul 2024

We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we a...

Insider Monkey · via Yahoo Finance 18 Jun 2024

Revenue: Reported at $190K for Q1 2024, significantly below estimates of $3.33M.Net Loss: Increas...

GuruFocus.com via Yahoo Finance 10 May 2024

Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company, is set to...

Investing.com 4 Apr 2024

Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket

Investing.com 1 Apr 2024

Shares of Doma Holdings Inc. DOMA rose sharply in today’s pre-market trading after the company e...

Benzinga 1 Apr 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on M...

Benzinga 1 Apr 2024

The U.S. FDA has delayed the review of Applied Therapeutics' NDA for rare drug disease candidate...

Seeking Alpha 28 Mar 2024

The U.S. Food and Drug Administration (FDA) has extended its review of the New Drug Application...

Investing.com 27 Mar 2024